Enavate Sciences GP, LLC
Enavate Sciences GP, LLC reported 7 US-listed holdings worth $345.4 million in its 13F for the quarter ended 30 June 2026, filed 14 August 2026. Its largest: Sionna Therapeutics Inc (31.6%), Zenas Biopharma Inc. (28.8%) and Immunome Inc. (22.2%). Against the quarter before, it opened 0 positions, added to 0, trimmed 1 and sold out of 0.
The 7 largest of its 7 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.
What the fund reported holding at each quarter's end; hover a bar for the number of positions
What its reported holdings returned
Held through each quarter, the holdings it reported returned +81.4% over the 6 quarters to 30 June 2026, against +27.4% for the S&P 500.
Not the fund's own return: each 13F's holdings are kept unchanged until the next one, so trades inside a quarter, dividends, cash and fees are left out. A rough guide to how its picks have done over time.
What it did on the quarter
Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held
Trimmed 1
- CAMP4 Therapeutics Corp. CAMP-765,379 shares · -35%
What it holds
| Company | Shares | Value | Of its book | Change in shares |
|---|---|---|---|---|
| Sionna Therapeutics Inc SION | 2.5M | $109.0 million | 31.56% | no change |
| Zenas Biopharma Inc. ZBIO | 3.9M | $99.5 million | 28.80% | no change |
| Immunome Inc. IMNM | 3.6M | $76.6 million | 22.17% | no change |
| Bridgebio Oncology Therapeutics Ord BBOT | 2.6M | $20.0 million | 5.80% | no change |
| Compass Therapeutics Inc. CMPX | 7.8M | $17.1 million | 4.94% | no change |
| Upstream Bio Inc. UPB | 2.5M | $17.0 million | 4.93% | no change |
| CAMP4 Therapeutics Corp. CAMP | 1.4M | $6.2 million | 1.80% | -765.4K |